City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Amrita Y. Krishnan, MD  
Search results:  11  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-11 Trials Jump to page:

COH Protocol Number: 15155

Principal Investigator: Amrita Krishnan, MD
Sponsor: Institutional

Title:  Single Patient Access Protocol for Patient "AZ": Daratumumab for Treatment of Multiple Myeloma

COH Protocol Number: 15104

Principal Investigator: Amrita Krishnan, MD
Sponsor: Institutional

Title:  Expanded Access Single Named Patient Program with Elotuzumab (BMS-901608) for the Treatment of a Patient with Relapsed/ Refractory Multiple Myeloma

COH Protocol Number: 15103

Principal Investigator: Amrita Krishnan, MD
Sponsor: Institutional

Title:  Expanded Access Single Named Patient Program with Elotuzumab (BMS-901608) for the Treatment of a Patient with Relapsed/ Refractory Multiple Myeloma

COH Protocol Number: 15054

Principal Investigator: Amrita Krishnan, MD
Sponsor: Institutional

Title:  Expanded Access Single Named Patient Program with Elotuzumab (BMS-901608) for the Treatment of a Patient with Relapsed/ Refractory Multiple Myeloma

COH Protocol Number: 14304 ClinicalTrials.gov Number: NCT02322320

Principal Investigator: Amrita Krishnan, MD
Sponsor: NCI Approved External Peer Review

Title:  BMT CTN 07LT: Continued, Long-Term Follow–Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702

COH Protocol Number: 14212 ClinicalTrials.gov Number: NCT01998971

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMaxCD38) (Anti-CD38 Monoclonal Antibody) in Combination with Backbone Regimens for the Treatment of Subjects with Multiple Myeloma

COH Protocol Number: 14156 ClinicalTrials.gov Number: NCT02223598

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  A Phase 1, Dose-Escalation /Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Patients with Relapsed/Refractory Multiple Myeloma

COH Protocol Number: 13336 ClinicalTrials.gov Number: NCT01208662

Principal Investigator: Amrita Krishnan, MD
Sponsor: Institutional

Title:  A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age.

COH Protocol Number: 13282 ClinicalTrials.gov Number: NCT01961063

Principal Investigator: Amrita Krishnan, MD
Sponsor: Institutional

Title:  Safety and Feasibility of Gene Transfer After Frontline Chemotherapy for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs

COH Protocol Number: 12338 ClinicalTrials.gov Number: NCT02366663

Principal Investigator: Amrita Krishnan, MD
Sponsor: Institutional

Title:  SPINOZA Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma

COH Protocol Number: 08102 ClinicalTrials.gov Number: NCT00628498

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study (Under CFR 312.34)

 
Results per page: 25 50 100 All 1-11 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.